Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease

被引:7
|
作者
Alvarez, Yulith Roca [1 ,2 ,3 ]
Pico, Madison [1 ,2 ,4 ]
Ashokprabhu, Namrita [1 ,2 ]
Abou-Amro, Kareem [1 ,2 ]
Bailey, Samantha [1 ,2 ]
Pung, Elizabeth [1 ,2 ]
Oberholster, Evan [3 ]
Quesada, Odayme [1 ,2 ,5 ]
机构
[1] Christ Hosp, Womens Heart Ctr, Heart & Vasc Inst, Cincinnati, OH 45219 USA
[2] Christ Hosp Hlth Network, Carl & Edyth Lindner Ctr Res & Educ, 2123 Auburn Ave Suite 424, Cincinnati, OH 45219 USA
[3] Kettering Hlth, Kettering, OH USA
[4] Univ Cincinnati, Sch Med, Cincinnati, OH USA
[5] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45221 USA
基金
美国国家卫生研究院;
关键词
Polycystic ovarian syndrome; PCOS; Cardiovascular disease risk; Subclinical cardiovascular risk; INTIMA-MEDIA THICKNESS; CORONARY-ARTERY CALCIFICATION; ENDOTHELIAL FUNCTION; SCIENTIFIC STATEMENT; FOLLOW-UP; WOMEN; ASSOCIATION; METAANALYSIS; METFORMIN; PREVALENCE;
D O I
10.1007/s11883-023-01168-1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Purpose of ReviewCharacterize the risk of cardiovascular disease (CVD) in individuals with polycystic ovarian syndrome (PCOS). Review the pathophysiological pathways that confers CVD risk in individuals with PCOS and interventions to reduce CVD risk.Recent FindingsPCOS is a complex syndrome characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries that has metabolic and cardiovascular implications. Intrinsic hormonal dysregulation and chronic low-grade inflammation play an important role in the progression of atherosclerosis in young premenopausal individuals and development of CVD independently of associated traditional risk factors. Management with metformin reduces CVD risk by reducing atherosclerosis progression.SummaryPCOS is an important CVD risk factor among individuals of reproductive age. Early detection and interventions are needed to mitigate development of CVD.
引用
收藏
页码:1003 / 1011
页数:9
相关论文
共 50 条
  • [41] Cardiovascular risk and events in polycystic ovary syndrome
    Carmina, E.
    CLIMACTERIC, 2009, 12 : 22 - 25
  • [42] The role of hyperinsulinemia as a cardiometabolic risk factor independent of obesity in polycystic ovary syndrome
    Csenteri, Orsolya Karola
    Sandor, Janos
    Kalina, Edit
    Bhattoa, Harjit Pal
    Godeny, Sandor
    GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (01) : 34 - 38
  • [43] Polycystic ovary syndrome and cardiovascular risk profile
    Bohlen, Sophia-Marie
    Kiesel, Ludwig
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2024, 22 (03): : 216 - 220
  • [44] Clinical Variability in Cardiovascular Disease Risk Factor Screening and Management in Adolescent and Young Adult Women with Polycystic Ovary Syndrome
    Baer, Tamara E.
    Milliren, Carly E.
    Walls, Courtney
    DiVasta, Amy D.
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2015, 28 (05) : 317 - 323
  • [45] Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis
    Li, Zhen
    Wang, Yu-Hua
    Wang, Lin-Lin
    Hu, Ding-Tao
    Teng, Ying
    Zhang, Ting-Yu
    Yan, Zi-Ye
    Wang, Fang
    Zou, Yan-Feng
    SCOTTISH MEDICAL JOURNAL, 2022, 67 (03) : 109 - 120
  • [46] The Correlation Between Polycystic Ovary Syndrome and Cardiovascular Disease Risk
    Cakir, Evrim
    Cakal, Erman
    Ozbek, Mustafa
    Sahin, Mustafa
    Delibasi, Tuncay
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 17 (02) : 33 - 37
  • [47] Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome
    Orio, Francesco
    Muscogiuri, Giovanna
    Nese, Cinar
    Palomba, Stefano
    Savastano, Silvia
    Tafuri, Domenico
    Colarieti, Giorgio
    La Sala, Giovanbattista
    Colao, Annamaria
    Yildiz, Bulent O.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 207 : 214 - 219
  • [48] Subclinical cardiovascular disease and polycystic ovary syndrome
    Gomez, Joanne Michelle D.
    VanHise, Katherine
    Stachenfeld, Nina
    Chan, Jessica L.
    Merz, Noel Bairey
    Shufelt, Chrisandra
    FERTILITY AND STERILITY, 2022, 117 (05) : 912 - 923
  • [49] The rs16944 SNP in IL-1B and risk of polycystic ovarian syndrome
    Saleh-Gargari, Soraya
    Ghafouri-Fard, Soudeh
    Zandieh, Zahra
    Ansaripour, Soheila
    Pouresmaeili, Farkhondeh
    Vatannejad, Akram
    GENE REPORTS, 2019, 17
  • [50] Fibroblast growth factor 23 and 25(OH)D levels are related to abdominal obesity and cardiovascular risk in patients with polycystic ovarian syndrome
    Gateva, Antoaneta
    Tsakova, Adelina
    Hristova, Julieta
    Kamenov, Zdravko
    GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (05) : 402 - 405